Aaron Goodman: How to choose between the 2 new BCMA directed bispecifics in myeloma?

Quoting on Aaron Goodman, Hematologist/Bone marrow transplanter at UCSD:

“How to choose between the 2 new (B-cell maturation antigen) BCMA directed bispecifics in myeloma?

Erlantamab is eventually given every 2 weeks as opposed to teclistamab every week for ever.

They will never be compared in RCT and both cost a huge amount of money this is all I have.

So I use erlantamab.”

Source: Aaron Goodman/Twitter